Compare Matson Inc (MATX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs BIO-TECHNE Corp — how do they compare? Matson Inc trades at $205 (market cap $6.24B), while BIO-TECHNE Corp trades at $72.16 (market cap $11.24B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and Matson Inc pays the higher dividend (0.73%). Which is the better fit depends on your goals.
| MATX | TECH | |
|---|---|---|
Market Cap | $6.24B | $11.24B |
Sector | Technology | Health |
52-Week High | $223.55 | $72.29 |
52-Week Low | $88.05 | $43.31 |
Enterprise Value | $6.84B | $11.32B |
Dividend Yield | 0.73% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $206.77, up 0.25% today, with strong technical momentum showing bullish moving averages and support at $205. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $4.27 versus $3.79 expected, and has raised full-year guidance. Valuation remains attractive with a P/E of 14.08 and EV/EBITDA of 7.93, while profitability metrics show a net income margin of 13.41% and ROE of 17.21%.
Outlook remains positive with analyst consensus pointing to 27% upside to $265 price target, supported by continued momentum in China services and resilient consumer demand. Key risks include exposure to Trans-Pacific trade volatility and competitive pressures in shipping markets. The combination of earnings momentum, reasonable valuation, and institutional support suggests favorable risk-reward for investors.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
